Clinical development of bromodomain and extra‐terminal (BET) protein inhibitors differs
from the traditional course of drug development. These drugs are simultaneously being …

Epigenetics mainly refers to covalent modifications to DNA or histones without affecting
genomes, which ultimately lead to phenotypic changes in cells or organisms. Given the …

Head and neck cancer affects the upper aerodigestive tract and is the sixth leading cancer
worldwide by incidence and the seventh by cause of death. Despite significant advances in …

Effective inhibition of the protein derived from cellular myelocytomatosis oncogene (c-Myc) is
one of the most sought-after goals in cancer therapy. While several c-Myc inhibitors have …

Acute graft-versus-host disease (GVHD) is the leading cause of non-relapse mortality
following allogeneic hematopoietic cell transplantation. The majority of patients non …

Objective To investigate the effects of bromine domain protein 4 (BRD4) inhibitor JQ1 on the
expression profile of super-enhancer-related lncRNAs (SE-lncRNAs) and mRNAs in cervical …

Background Type II germ cell tumors represent the most common solid malignancy in men
aged 15–45 years. Despite high cure rates of> 90% over all stages, 10–15% of advanced …

Proteins of the bromodomain and exterminal domain (BET) family mediate critical host
functions such as cell proliferation, transcriptional regulation, and the innate immune …

Background The third-generation epithelial growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) have shown significant therapeutic effects on patients with non-small cell lung …

Thyroid cancer is the most common endocrine carcinoma and, among its different subtypes,
the papillary subtype (PTC) is the most frequent. Generally, PTCs are well differentiated, but …